Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder

References

• Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201. doi:10.1128/CMR.00037-09
   PubMed Web of Science ®Google Scholar
• Su J, Guo Q, Li Y, et al. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3176–3180. doi:10.1093/jac/dky323
   PubMed Web of Science ®Google Scholar
• Xin X, Jian L, Xia X, et al. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob. 2013;12(1):38. doi:10.1186/1476-0711-12-38
   PubMedGoogle Scholar
• Greenberg RN, Reilly PM, Weinandt WJ, Bollinger M, Kennedy DJ. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation. Clin Ther. 1987;10(1):52–56.
   PubMed Web of Science ®Google Scholar
• Wong RS, Cheng G, Chan NP, Wong WS, Ng MH. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency. Am J Hematol. 2006;81(1):76. doi:10.1002/ajh.20449
   PubMed Web of Science ®Google Scholar
• Cai Z, Yang W, He Y, et al. Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: a case report and review of the literature. Drug Saf Case Rep. 2016;3(1):2. doi:10.1007/s40800-016-0025-9
   PubMedGoogle Scholar
• Lipsky JJ. N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia. Lancet. 1983;2(8343):192–193. doi:10.1016/s0140-6736(83)90174-5
   PubMed Web of Science ®Google Scholar
• Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. 1999;8(2):81–94. doi:10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Mueller RJ, Green D, Phair JP. Hypoprothrombinemia associated with cefoperazone therapy. South Med J. 1987;80(11):1360–1362. doi:10.1097/00007611-198711000-00007
   PubMed Web of Science ®Google Scholar
• Chen LJ, Hsiao FY, Shen LJ, et al. Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: a nationwide nested case-control study. PLoS One. 2016;11(7):e0158407. doi:10.1371/journal.pone.0158407
   PubMed Web of Science ®Google Scholar
• Group of Infectious Diseases RDBoCMA. Guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia of adults in China. Chin J Tuberculosis Respir Dis. 2018;41(4):255–280.
   Google Scholar
• Liu H, Jia X, Zou H, et al. Detection and characterization of tigecycline heteroresistance in E. cloacae: clinical and microbiological findings. Emerg Microbes Infect. 2019;8(1):564–574. doi:10.1080/22221751.2019.1601031
   PubMed Web of Science ®Google Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–547. doi:10.1016/j.cmi.2021.11.025
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015;41(12):2057–2075. doi:10.1007/s00134-015-4079-4
   PubMed Web of Science ®Google Scholar
• Pfizer. Tygacil (tigecycline) for injection [prescribing information]. PA; 2013.
   Google Scholar
• Guo J, Ma J, Wang S, et al. Valproic acid after neurosurgery induces elevated risk of liver injury: a prospective nested case-control study. Ann Pharmacother. 2022;56(8):888–897. doi:10.1177/10600280211055508
   PubMed Web of Science ®Google Scholar
• Rafa E, Kolpa M, Walaszek MZ, et al. Healthcare-acquired infection surveillance in neurosurgery patients, incidence and microbiology, five years of experience in two polish units. Int J Environ Res Public Health. 2022;19(12):7544. doi:10.3390/ijerph19127544
   PubMed Web of Science ®Google Scholar
• Abdallah C. Considerations in perioperative assessment of valproic acid coagulopathy. J Anaesthesiol Clin Pharmacol. 2014;30(1):7–9. doi:10.4103/0970-9185.125685
   PubMedGoogle Scholar
• Sharma A, Sanchez J, Dew M, Shergill G. Valproate-associated transaminitis and rhabdomyolysis. Cureus. 2023;15(4):e38348. doi:10.7759/cureus.38348
   PubMedGoogle Scholar
• Yuanchao Zhu LL, Shen J. Clinical features and risk factors of coagulation disorders caused by cefoperazone sodium and sulbactam sodium. Chin Pharm J. 2022;57(9):741–746.
   Google Scholar
• Shao X, Ren Y, Xie N, et al. Effect of cefoperazone/sulbactam on blood coagulation function in infected emergency department patients and the necessity of Vitamin K1 (VK1) preventive intervention: a single-center, retrospective analysis. Med Sci Monit. 2023;29:e939203. doi:10.12659/MSM.939203
   PubMed Web of Science ®Google Scholar
• Wu S, Wu G, Wu H. A comparison of coagulation function in patients receiving aspirin and cefoperazone-sulbactam with and without vitamin K(1): a retrospective, observational study. Clin Ther. 2021;43(12):e335–e345. doi:10.1016/j.clinthera.2021.10.005
   PubMed Web of Science ®Google Scholar
• Yuying Wang JY, Duan J. Analysis of influencing factors of coagulation dysfunction caused by cefoperazone sulbactam. Chin General Pract. 2020;23(S1):138–140.
   Google Scholar
• Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325–332. doi:10.2147/TCRM.S302850
   PubMed Web of Science ®Google Scholar
• McMahan J, Moenster RP. Tigecycline-induced coagulopathy. Am J Health Syst Pharm. 2017;74(3):130–134. doi:10.2146/ajhp150894
   PubMed Web of Science ®Google Scholar
• Zhang L, Cai X, Peng F, et al. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies. Front Pharmacol. 2023;14:1182644. doi:10.3389/fphar.2023.1182644
   PubMed Web of Science ®Google Scholar
• Treml B, Rajsic S, Hell T, Fries D, Bachler M. Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis. J Clin Med. 2021;10(20):4702. doi:10.3390/jcm10204702
   PubMed Web of Science ®Google Scholar
• Chen HF, Xu LP, Luo ZY, et al. Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review. Drug Des Devel Ther. 2013;7:767–770. doi:10.2147/DDDT.S47718
   PubMed Web of Science ®Google Scholar
• Meng QGH. Literature Analysis on 322 Cases of Fibrinogen Reduction Induced by Valproate. China Pharmacist. 2019;22(2):144–147.
   Google Scholar